Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Two Approvals, One new QIDP, One rejection and a BLA withdrawal

3/26/2019

 
FDA Actions

The FDA approved solriamfetol (Sunosi, Jazz Pharmaceuticals) on 3/20/2019 to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

The FDA approved brexanolone (Zulresso, Sage Therapeutics)on 3/19/2019 for the treatment of postpartum depression. 

The FDA granted Qualified Infectious Disease Product (QIDP)to the oral and IV formulations of sulopenem in March 2019.  

The FDA rejected sotagliflozin on 3/22/2019.Lexicon and Sanofi are working with the FDA to determine future development of the drug. 

Spectrum withdrew the BLA for eflapegrastimto provide more information to the FDA on the chemistry, manufacturing and controls process.

Two
Trials Published

In a draft cost-effectiveness analysis, ICER estimated a quality-adjusted life year of $826,000 for use of siponimod in the treatment of secondary progressive multiple sclerosis, assuming the same cost for siponimod as ocrelizumab.

In a 48-hour, 389 patient, Phase III trial, 50% of Trevena’s oliceridine 0.1 mg patients, 62% of 0.35 mg patients and 65.8% of 0.5 mg patients reached the combination endpoint of a 30% or > improvement in pain (SPID-48), received no rescue drugs, completed the study period and did not reach dosing limits compared to with 15.2% that received placebo in patients with moderate-to-severe pain following bunionectomy. The 0.35 mg and 0.5 mg doses were non-inferior to morphine in reaching the primary endpoint. In a 389 patient, Phase III trial, GI ADR increased in a dose-dependent manner in oliceridine regimens; 40.8% with 0.1 mg, 59.5% with 0.35 mg and 70.9% with 0.5 mg compared to 24.1% with placebo and 72.4% with morphine.

Five Announced Investigational Drug Developments
  1. Demira announced that in a 16-week, 280 patient, Phase Ib trial, lebrikizumab improved the EASI score by 62.3% in patients receiving 125 mg every four weeks, 69.2% with 250 mg every four weeks and 72.1% for patients receiving 250 mg every two weeks compared to a 41.1% improvement with placebo in patients with moderate-to-severe atopic dermatitis. Dermira plans to initiate Phase III trials at the end of 2019.
  2. Urovant announced that in the 12-week, 1,518 patient, Phase III, EMPOWUR trial, treatment with vibegron reduced micturitions per 24 hours and urge urinary incontinence episodes per 24 hours compared to placebo in patients with overactive bladder. Vibegron was no different than tolterodine in the trial. Compared to placebo, vibegron reduced both primary endpoints as early as two weeks. Urovant enrolled 507 patients from the EMPOWUR trial in a 40-week RCT extension trial to evaluate the safety of longer-term treatment of vibegron. The FDA accepted the BLA for AR101 and set a PDUFA date for late January 2020.
  3. GenNeuro announced that in the ANGEL-MS trial, a 96-week, 154 patient, extension of the Phase IIb CHANGE-MS trial, where the highest dose of temelimab (18mg/kg) had 2.4% of patients develop worsening of 20% or more in the Timed 25-Foot Walk Test compared to 10.2% with placebo in patients with multiple sclerosis. There was no statistical difference in worsening in neurological disability between temelimab and placebo.
  4. Biogen and Eisai announcedthat an interim analysis by an independent committee of the Phase III aducanumab trials ENGAGE and EMERGE involving patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia were unlikely to meet their primary endpoints resulting in a discontinuation of both studies. Biogen also discontinued a Phase II safety trial and long-term extension of a Phase Ib trial. Biogen is considering whether to initiate a Phase III secondary prevention trial.
  5. Conatus announced that in the 72-week, 318 patient, Phase IIb, ENCORE-NF trial, emricasan did not improve the CRN fibrosis stage without suffering a worsening of steatohepatitis compared to placebo in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.